Volume 30, Issue 2, 2021
DOI: 10.24205/03276716.2020.4073
Efficacy and safety of ligliptin in treatment of fragile diabetes mellitus complicated with early diabetic nephropathy
Abstract
At present, the treatment approaches for patients with diabetes and early nephropathy are still mainly based on insulin. Drugs with lower renal excretion rate such as repaglinide and acarbose were commonly applied control the continued loss of urinary protein. However, the current treatment effect of patients with brittle diabetes complicated with early kidney disease is still unsatisfactory. Therefore, it is urgently required to control blood glucose smoothly and delay the progression. Eighty patients with brittle diabetes mellitus complicated with early diabetic nephropathy were randomly assigned into treatment group and control group. Apart from insulin and benazepril, the treatment group took oral linagliptin and control group took oral placebo for 12 weeks followed by analysis of the fasting blood glucose (FPG), postprandial 2h blood glucose (2hPBG), glycosylated hemoglobin (HbA1C), blood lipid level, urinary albumin excretion rate (UAER), and Cystatin C (Cys C). Meanwhile, the serum C-reactive protein (CRP), IL-6, IL-10, and TNF-? levels before and after treatment were determined by ELISA. There were no significant differences in FPG, 2hPBG, HbA1C, UAER, Cys C, CRP, and IL-6 levels before treatment (P > 0.05), but they were significantly decreased after treatment (P < 0.05). IL-10 and TNF-? showed no difference before or after treatment between two groups (P > 0.05). IL-10 was increased and TNF-? was reduced after treatment (P < 0.05). There were 8 patients with adverse reactions in treatment group (20%) and 7 cases in control group (17.5%) (P > 0.05). Linagliptin can effectively control the blood glucose level of patients with brittle diabetes complicated with early diabetic nephropathy and improve the UAER by reducing inflammatory response.
Keywords
linagliptin, brittle diabetes, diabetic nephropathy, efficacy, safety